

# Andr Plegrin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2037961/andre-pelegrin-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15  
papers

551  
citations

12  
h-index

21  
g-index

21  
ext. papers

707  
ext. citations

6.8  
avg, IF

2.86  
L-index

#	Paper	IF	Citations
15	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. <i>MAbs</i> , <b>2021</b> , 13, 1914883	6.6	0
14	Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using In-Labeled SGM-101. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5934-5942	12.9	3
13	Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients. <i>Toxicology Reports</i> , <b>2019</b> , 6, 409-415	4.8	9
12	Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 181-191	18.8	87
11	Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3350-3357	3.1	64
10	SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery. <i>Surgical Oncology</i> , <b>2017</b> , 26, 153-162	2.5	39
9	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial. <i>Oncotarget</i> , <b>2015</b> , 6, 12796-808	3.3	43
8	HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. <i>Oncotarget</i> , <b>2014</b> , 5, 7138-48	3.3	29
7	High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging. <i>Journal of Immunological Methods</i> , <b>2013</b> , 387, 11-20	2.5	8
6	In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptorsb down-regulation and dimersbdisruption. <i>Neoplasia</i> , <b>2012</b> , 14, 121-30	6.4	57
5	In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3356-62	12.9	63
4	Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy. <i>International Journal of Cancer</i> , <b>1996</b> , 67, 294-302	7.5	13
3	Different behaviour of mouse-human chimeric antibody F(ab) <sub>2</sub> fragments of IgG1, IgG2 and IgG4 sub-class in vivo. <i>International Journal of Cancer</i> , <b>1992</b> , 50, 416-22	7.5	22
2	Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of antibodies in nude rats and as rejection antigen in syngeneic rats. <i>International Journal of Cancer</i> , <b>1992</b> , 52, 110-9	7.5	16
1	Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. <i>Cancer</i> , <b>1991</b> , 67, 2529-37	6.4	74